An upbeat handover from Wall Street on Thursday inspired gains in most Asian shares on Friday.» Read More
CNBC's David Faber reports the latest details on Illumina's recommendation to shareholders to reject Roche's takeover offer.
A serious warning is out to patients, doctors and hospitals telling everyone to beware of a fake version of Roche's cancer-fighting drug Avastin. Insight with Scott Gottlieb, MD.
Considering Illumina just adopted a poison pill defense strategy, you might think a deal with Roche is out of the question. But Karen Finerman says it's not.
Karen Finerman, Metropolitan Capital Advisors, and Fast Money trader, provides insight on what's next for Illumina, on the heels its recent rejection of Roche's offer.
Insight on the value that will be created by a transaction with Illumina, with Severin Schwan, Roche CEO, who discusses Roche's offer for Illumina.
European stocks were called to open higher on Wednesday tracking Asia overnight where shares rose on better-than-expected manufacturing data out of China.
Stocks ended near session highs Wednesday, reversing their early declines, as the market cheered news that the Fed will not raise interest rates until at least 2014 in addition to maintaining its highly accommodative stance to support the recovery.
Illumina landed squarely on Karen Finerman’s trader radar Wednesday with the company in the cross hairs of a hostile bid from Roche.
Keith Moore, MKM Partners, discusses how to play Roche's hostile bid for gene sequencer, Illumin, saying ILMN is likely to fight the takeover. Also an update on SanDisk's earnings, with the Fast Money crew.
Fast Money trader Karen Finerman explains what's behind Roche's tender offer for Illumina; and the best way to play the biotech takeout trend.
CNBC's David Faber has the details on Roche's Illumina offer worth $44.50 per share in cash.
U.S. stock index futures struggled for direction Wednesday as investors digested a handful of corporate earnings and ahead of the Federal Reserve's policy statement.
Severin Schwan, CEO of Roche, made his first appearance on CNBC, to discuss the pharmaceutical giant's third quarter earnings.
Swiss pharmaceutical giant, Roche, is due to release its Q3 sales results on Thursday. Amit Roy, head of healthcare equity research at Nomura and Barath Subramanian, healthcare senior consultant at Frost & Sullivan, joined CNBC to discuss what we can expect, and how the pharmaceutical sector as a whole is holding up.
U.S. drug regulators approved a targeted skin cancer drug from Roche Holding, offering new hope for patients with the deadliest form of cancer after years of few options.
The fate of the world's best-selling cancer medicine is in the hands of the FDA. There's a lot at stake for Roche and the thousands of women who take the drug, reports CNBC's Hampton Pearson.
A look at how Roche has recently received a boost from regulators for its key medications, with Hal Barron, Roche chief medical officer.
These more targeted, or niche, drugs might only treats thousands, but they could yield higher success rates for patients and lower marketing costs for the industry.
Roche's cancer drug Avastin remains a growth driver for the company despite disappointing sales in the US and Europe as a result of regulatory restrictions, Chief Executive Severin Schwan told CNBC on Thursday.
With the markets on a decline, investors need to put money into value plays, said Rob Hoxton, president and CEO of Hoxton Financial, and Robert Auer, portfolio manager at Auer Growth Fund.